(NewMediaWire) – December 20, 2021 – DALLAS – The Omicron variant currently represents 3-13% of new COVID-19 infections in the U.S., and it appears to be much more contagious than the Delta variant. COVID-19 vaccination is more important than ever. The American Heart Association continues to align with expert guidance from the U.S. Centers for Disease Control and Prevention (CDC), the nation’s infectious disease experts, regarding COVID-19 vaccines and boosters.
Last Thursday, the CDC recommended the mRNA COVID-19 vaccines as the preferred vaccines for most adults. The two-dose mRNA vaccines, produced by Pfizer-BioNTech or Moderna, are preferred rather than the single-dose, adenovirus-vector vaccine from Johnson & Johnson (Janssen). The new recommendation is in response to recent data indicating an increased risk of a rare condition called thrombosis with thrombocytopenia syndrome (TTS; also known as vaccine induced thrombocytopenia with thrombosis, or VITT) after receiving the Johnson & Johnson COVID-19 vaccine.
TTS is the combination of low blood platelet count (thrombocytopenia) and thrombosis. One type of thrombosis associated with TTS is cerebral venous sinus thrombosis (CVST), which refers to blood clots in the brain’s veins – not in the arteries, as is the case for most strokes. CVST is a rare but serious type of stroke caused by a blood clot in a part of the brain known as the venous sinus, involving veins that carry blood away from the brain. CVST clot symptoms are very similar to several other neurological conditions, and the symptoms may include:
- severe headache;
- blurry vision;
- fainting or loss of consciousness;
- sensory changes;
- confusion or trouble speaking;
- nausea and vomiting; or
CVST occurs in the veins of the brain. In addition to CVST, other types of thrombosis associated with TTS include clotting in the veins of the legs (deep vein thrombosis or DVT), lungs (pulmonary embolism or PE), and abdomen. Symptoms associated with these other types of thrombosis include abdominal pain, leg pain, difficulty breathing or shortness of breath.
Among the TTS cases reported in the U.S., the most common symptoms were severe headaches; vomiting; back pain; fatigue; weakness or the inability to move one side of the body (hemiparesis); inability to speak or understand speech (aphasia); loss of consciousness; and abdominal pain.
Cases of TTS occurred several days after being vaccinated with the one-dose Johnson & Johnson COVID-19 vaccine. From March 2 through August 31, 2021, there were 54 cases of hospitalized patients with TTS in the U.S., out of 14.1 million doses of the Johnson & Johnson vaccine administered, representing a case rate of 3.8 cases per million doses. The 54 documented cases of TTS were adults ages 28-62, the majority of whom were women (37 women vs. 17 men). There are no reports to-date of TTS after receiving the Johnson & Johnson vaccine as a booster dose. 
“The CDC’s latest data indicate that TTS is a rare, yet serious, possible side effect after receiving the Johnson & Johnson COVID-19 vaccine. Individuals who receive the Johnson & Johnson COVID-19 vaccine should be monitored for symptoms of TTS and seek immediate treatment,” said American Heart Association volunteer expert and co-author of the Association’s April 2021 special report on TTS, Mary Cushman, M.D., M.Sc., professor of medicine and co-director of the Vermont Center for Cardiovascular and Brain Health at University of Vermont’s Larner College of Medicine in Burlington, Vermont. The Association’s special report, Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Immune Thrombotic Thrombocytopenia, provides important guidance about TTS – the signs and symptoms and the best treatment options.
The American Heart Association/American Stroke Association, a global force for longer, healthier lives for all, affirms the CDC’s guidance on COVID-19 vaccines and boosters. The Association remains concerned about the continuing gaps in COVID-19 vaccination among people from all eligible age groups in the U.S., including people from diverse racial and ethnic groups and pregnant people, particularly given the new Omicron variant. The Association continues to recommend all adults and children ages 5 and older in the U.S. to receive the COVID-19 vaccine as soon as they are eligible, as recommended by the CDC and fully approved or authorized for emergency use by the FDA.
The following statement reflects the views of the American Heart Association/American Stroke Association and its science leaders:
- President Donald M. Lloyd-Jones, M.D., Sc.M., FAHA,
- Immediate Past President Mitchell S.V. Elkind, M.D., M.S., FAHA, FAAN,
- President-Elect Michelle A. Albert, M.D., M.P.H., FAHA,
- Chief Science and Medical Officer Mariell Jessup, M.D., FAHA, and
- Chief Medical Officer for Prevention Eduardo Sanchez, M.D, M.P.H., FAHA, FAAFP.
“The mRNA vaccines are the preferred vaccines for most adults, given the latest data on the rare, yet serious possible side effect of TTS after receiving the Johnson & Johnson COVID-19 vaccine. Despite the rare risk of TTS, the benefits of any of the three COVID-19 vaccines approved in the U.S. outweigh the risks of remaining unvaccinated.
“The Johnson & Johnson COVID-19 vaccine remains available in the U.S. and is recommended for people who cannot receive one of the mRNA vaccines due to an allergy or other medical reason, or anyone who does not want to receive an mRNA COVID-19 vaccine. It is also a good option for people who have limited access to receive the two required doses of the mRNA vaccines, including people with difficulty accessing health care, such as those who are homeless, living in remote areas, or in countries with fewer health care resources. Individuals who receive the Johnson & Johnson COVID-19 vaccine should be monitored for symptoms of TTS and seek treatment as quickly as possible. Please consult with a health care professional if you have any questions about which COVID-19 vaccine may be most appropriate for you or a loved one.
“With the Omicron variant rapidly spreading throughout the U.S., we urge everyone 5 and older to get vaccinated against COVID-19 and get a booster dose as soon as they are eligible. Boosters are particularly important for adults ages 50 and older who have underlying medical conditions or any adult living in a long-term care facility.
“COVID-19 vaccination and boosters are our #1 defense to saving lives and protecting our families and loved ones against COVID-19 infection, severe illness and death. The benefits of the vaccine and boosters far outweigh the very limited, rare adverse events. The CDC’s safety protocols continue to include mask wearing for all people regardless of vaccination status when indoors, frequent handwashing and social distancing.
“Here in the U.S., we are incredibly fortunate to have multiple vaccination choices. The American Heart Association implores everyone to get vaccinated as soon as possible.”
The Association receives funding primarily from individuals. Foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.
About the American Heart Association/American Stroke Association
The American Heart Association is a relentless force for a world of longer, healthier lives and includes the American Stroke Association. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
Michelle Kirkwood: 703-457-7838, email@example.com